Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Lexapro: The First Victim of Part D?

This article was originally published in RPM Report

Executive Summary

A slowdown in sales of Forest's flagship antidepressant Lexapro left analysts confused: generic versions of Celexa seem to be weighing down the new product, but why did the impact suddenly arrive in the third quarter? A recently policy pronouncement from CMS may be a clue.

You may also be interested in...

Defining Line Extensions: Medicaid Rebate Change Gives CMS Power to take a Bite Out of Lifecycle Management

A new provision in the health care reform law means that new formulations of oral brand name drugs will be subject to additional rebates. But who is affected depends in part on how CMS defines a line extension.

Biopharma in 2008: What a Difference an Economic Crisis Makes

Even before the financial meltdown, 2008 was a remodeling year for the biopharmaceutical world. Many pharma companies, more reliant on the product candidates and technologies of the biotech world than ever, were pinned down by excess infrastructure and lagging productivity. But when the world's cash dried up, so, too, did biotech's leverage over those downtrodden in-licensers and acquirers. We highlight some top trends from a difficult year that may shape industry in 2009 and beyond.

Paying for Protection: Medicare Rebates May Make Protected Classes Less Safe for Sponsors

Democrats failed in their first attempt to impose price controls in Medicare Part D. But, led by California Rep. Waxman, they may have found a new approach that seems less threatening than price negotiations-rebates for products used by dual eligible patients. And the drugs most likely to be affected are in Part D's six protected classes.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts